


Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors



Authors

Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, Rafael Álvarez, Teresa Macarulla, Maria C. Riesco-Martinez, Helena Verdaguer, Carmen Guillén-Ponce, Martí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Natalia del Pozo, Jaime Martínez de Villarreal, Francisco X. Real, Noemí Vidal, Gabriel Capella, Ramon Alemany, Emma Blasi, Carmen Blasco, Manel Cascalló, Ramon Salazar

Correspondence

ramonsalazar@iconcologia.net

In Brief

VCN-01 is an oncolytic adenovirus designed for systemic administration, that expresses hyaluronidase selectively in tumor cells and favors the entry of chemotherapy and the immune system.

Intravenous treatment with VCN-01 is feasible and has an acceptable safety.

Active replication of VCN-01 and induction of inflammatory response in tumors was demonstrated after intravenous administration.

Encouraging biological and clinical activity was observed when administered in combination with nab-paclitaxel plus gemcitabine to patients with pancreatic adenocarcinoma.